UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib

May 01, 2023 10:01 am
Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
Links
https://bit.ly/42dzSoM
Show on Archive Page
On
Display in Search Results
On
PDQ
Off

    Do you get our email newsletter?

    Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

    Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

    Copyright 2023 All Rights Reserved.

    ×